Halozyme Reports Record Q2 Revenue Growth on ENHANZE Platform Expansion
The biopharmaceutical company posted 48% year-over-year revenue growth to $481 million, driven by diversified royalty streams and a flurry of new partnership agreements.
Record Quarter Driven by Royalty Diversification
Halozyme Therapeutics reported exceptionally strong second-quarter results, with total revenue climbing 48% year-over-year to $481 million, led by what CEO Dr. Helen Torley called the company's "compounding platform engine" delivering on multiple fronts (earnings call, 2026-08-06).
Royalty revenue reached a record $308 million in the quarter, representing 50% year-over-year growth. The performance was driven by increasing contributions from newer launches including OPDIVO SC, OCREVUS SC, and RYBREVANT SC, which collectively grew approximately 80% quarter-on-quarter, building on continued strong performance from established products DARZALEX SC, VYVGART Hytrulo, and PHESGO (earnings call, 2026-08-06).
The robust revenue translated to adjusted EBITDA of $329 million—a margin exceeding 65%—and non-GAAP earnings per share of $2.28 (earnings call, 2026-08-06).
Unprecedented Partnership Momentum
Halozyme signed four new collaboration and licensing agreements during the second quarter and a fifth in July, marking what Torley described as "the pace of new collaboration agreements in the history of Halozyme" the company has never before achieved (earnings call, 2026-08-06).
Three of the five agreements were for the company's ENHANZE platform, including new deals with GSK, Insight, and a confidential partner. Two agreements covered Hypercon, the company's next-generation platform, with Vertex and Oruka as partners. The partnerships expanded beyond monoclonal antibodies into antibody-drug conjugates (ADCs) and nucleic acid modalities, representing "brand new growth opportunity for ENHANZE" (earnings call, 2026-08-06).
These new agreements contributed $35.5 million in upfront collaboration revenue, split approximately evenly between ENHANZE and Hypercon (earnings call, 2026-08-06).
Product Performance Highlights
OCREVUS ZUNOVO demonstrated significant traction, with patient numbers increasing to 44,000 from 17,500 at the end of 2025's fourth quarter. Roche noted approximately 60% of U.S. starts came from community practices, showcasing how ENHANZE-enabled delivery reaches new care settings (earnings call, 2026-08-06). Roche reaffirmed expectations for CHF 9 billion in peak OCREVUS sales by 2029.
Bristol-Myers Squibb's OPDIVO Qvantig posted global sales growth exceeding 200% year-over-year to $261 million, with subcutaneous conversion reaching 15% and on track toward the targeted 30-40% range. The product is projected to exceed $1 billion in annualized revenue (earnings call, 2026-08-06).
DARZALEX continued robust growth at approximately 18% year-over-year to over $4 billion in quarterly sales, with virtually all sales coming from the subcutaneous formulation (earnings call, 2026-08-06). VYVGART total sales grew 60% year-over-year to $1.5 billion, with approximately 80% of U.S. prefilled syringe patients being new to therapy (earnings call, 2026-08-06).
Raised Guidance and Pipeline Expansion
Based on the strong second-quarter performance, Halozyme raised its full-year 2026 total revenue guidance by $110 million at the midpoint, driven by increased projected royalty revenues and upfront milestones from new partnerships (earnings call, 2026-08-06).
The company advanced two new Phase I studies during the quarter and remains on track for its goal of 13 ENHANZE development programs by year-end 2026, currently standing at nine. For Hypercon, the company is preparing clinical supply to support first clinical starts in the first half of 2027, with projected initial launches in 2030-2031 and expectations to achieve approximately $1 billion in royalty revenue in the mid-2030s (earnings call, 2026-08-06).
According to MarginX data, Halozyme is expected to report third-quarter 2026 results on November 3, 2026.
This article was generated by MarginX from the earnings call on 2026-08-06. It is not investment advice.